Ligand Pharmaceuticals Incorporated · NASDAQ:LGND
Ligand Pharmaceuticals — Investor Day (June 2011)
5 slides from Ligand Pharmaceuticals's investor day presentation, Jun 24, 2011
Slide 1: Revenue sources and drivers
Exhibit 99.2 Exhibit REVENUE 2011 LICENSE ROYALTIES VFEND ABILIFY MATERIAL NUMEROUS NUMBERS DEVELOPING PAST PRESENT FUTURE License Material NEWEST Royalty LIGAND BAXTER STRONG CXCR2 Carfilzomib Nexterone Promacta REVENUE ~67% 99.2 and Program GEODON Sales RECEIVES ~10% NEXTERONE ACQUIRED LAUNCHED CE
Slide 2: Captisol-enabled melphalan
Captisol-EnablEd, Pivotal >50,000 market melphal Product alkeran propylene develoPment orphan Financial addresses L the approVaL igand Bottom abiLity drUg is ‘advantages an patients soPPortunity $80+ cUrrently and glycol-free M to (alkeran) line designation status own eLphaL beyond mm inapG the pack
Slide 3: SARM LGD-4033
Phase Supportive preclinical sarm lgd-4033 sarM Unique Most clinical Ph. Well Potential commercial medical & lean Populations average the Ligand’s long-term Bottom Imass tolerated efficacy potent iiAR leg ready needs sarM to(kg) animal line binding Press address oral muscle trends with in prograM ch
Slide 4: Topical JAK3 inhibitor preclinical program
TOPICAL PRECLINICAL target Small-molecule Specific lower Jak3 Ligand Many Active Compounds No inhibition photocytotoxicity, cI(IL-2, JAK3 JAK1 IL-7 IL-15 homeostasis, activation, IL-21 IL-9 Ab T-cell diff, Activation, Transcription S P Differentiation, activation Stat5 the L-2 urvival cytokine Stat5
Slide 5: Fructose bisphosphatase discovery program
Fructose Pii Discovery glucagon Preclinical dgat glucokinase discovery Novel Ligand aboF in engage to opportunity the us giVes eassets cdM taboLic road oLL isease diabetes Bottom inhiBitor aboration dIABeteS s BisPhosPha-tase portFoLio recePtor line (gk) MeChANISM activator antagonist (FBP)ofinhiBit